OS 10.6 vs 7.8 months (HR 0.63). Established sequential TKI therapy.
Setting
HCC progressing on sorafenib: regorafenib vs placebo
Phase
Phase 3
Sponsor
Bayer
Registry
Headline result
OS 10.6 vs 7.8 months, HR 0.63.
Reported
2017
Enrolled
573
In plain words
What these results mean for people, not percentages
Overall survivalprimarysurvival endpoint
- Median 10.6 vs 7.8 months with Regorafenib compared with Placebo; about 2.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.5 to 0.79).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: HCC progressing on sorafenib: regorafenib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
573 participants enrolled.
Overall survivalprimary
HR 0.63 (0.5–0.79) · p <0.0001
Regorafenib
10.6 mo
Placebo
7.8 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Regorafenib | 379 | 10.6 months | 0.63 (0.5–0.79) | <0.0001 | — |
| Placebo | 194 | 7.8 months |
Pages like this
not linked directly; found by shared links- CompanyBayer
Shares Regorafenib, Hepatocellular carcinoma.
- PathwayThe angiogenic switch & tumour vessels
Shares Regorafenib, Hepatocellular carcinoma.